Last updated on April 2019

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia


Brief description of study

This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia.

Clinical Study Identifier: NCT03232177

Find a site near you

Start Over

Hallym UNIV. Medical Center

Anyang, Korea, Republic of
  Connect »

Inha University Hospital

Incheon, Korea, Republic of
  Connect »

Jeju National University Hospital

Jeju City, Korea, Republic of
  Connect »

Hallym UNIV. Medical Center

Seoul, Korea, Republic of
  Connect »